Clinical Trial Detail

NCT ID NCT01686165
Title Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of Arizona
Indications

anaplastic large cell lymphoma

diffuse large B-cell lymphoma

mantle cell lymphoma

non-Hodgkin lymphoma

Therapies

Belinostat

Rituximab

Age Groups: adult

No variant requirements are available.